You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Seattle, Washington 98109

  • Myelodysplastic Syndromes


RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients who have myelodysplastic syndrome.

Study summary:

OBJECTIVES: - Determine the frequency of hematologic responses in patients with myelodysplastic syndrome treated with anti-thymocyte globulin and tumor necrosis factor receptor IgG chimera. - Correlate phenotypic, cytogenetic, and functional disease characteristics with treatment responses in these patients. - Determine the safety of this treatment regimen in this patient population. OUTLINE: Patients receive anti-thymocyte globulin IV over 8 hours daily for 4 days followed by tumor necrosis factor receptor IgG chimera subcutaneously twice weekly for 16 weeks. Patients are followed at 8, 16, and 20 weeks. PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of myelodysplastic syndrome with no greater than 20% marrow blasts with: - Single or multilineage cytopenia (neutrophils less than 2,000/mm^3 and/or platelet count less than 100,000/mm^3 and/or reticulocyte count less than 18,000/mm^3) OR - Transfusion requirement of at least 2 units packed red blood cells per month and one of the following: - Suitable marrow donor unavailable - Ineligible for a transplantation protocol - Unwilling to proceed with transplantation - No chronic myelomonocytic leukemia PATIENT CHARACTERISTICS: Age: - Any age Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - See Disease Characteristics Hepatic: - Not specified Renal: - Not specified Other: - No other severe disease that would preclude study - No active severe infection (e.g., pneumonia or septicemia) or severe infections within the past 2 weeks PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - At least 4 weeks since prior hematopoietic growth factors - No concurrent hematopoietic growth factors Chemotherapy: - At least 4 weeks since prior cytotoxic therapy - No concurrent cytotoxic therapy Endocrine therapy: - Not specified Radiation therapy: - Not specified Surgery: - Not specified Other: - At least 4 weeks since prior immunomodulatory therapy - No concurrent immunomodulatory therapy



Primary Contact:

Study Chair
H. Joachim Deeg, MD
Fred Hutchinson Cancer Research Center

Backup Contact:


Location Contact:

Seattle, Washington 98109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.